Physician profile
Alyssa Smith
NPI 1477215952
$4,047.43
in general payments reported to CMS, 2019-2025
32 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $747 · 2023: $1,029 · 2024: $1,071 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.50 |
| Education | $120.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $926.56 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $641.63 | 2022-2025 | |
| Abbvie INC. | $278.40 | 2024-2025 | |
| Amgen INC. | $184.30 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $168.25 | 2022-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $167.04 | 2023-2025 | Onpattro |
| Harmony Biosciences LLC | $141.76 | 2022-2025 | Wakix |
| Esperion Therapeutics, INC. | $141.01 | 2023-2025 | Nexletol |
| Lilly USA, LLC | $132.10 | 2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $131.33 | 2024 | |
| Pfizer INC. | $109.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $99.99 | 2022-2025 | Farxiga, Brilinta |
| Axsome Therapeutics, INC. | $87.00 | 2023-2025 | Sunosi |
| Kowa Pharmaceuticals America, INC. | $84.00 | 2022-2024 | Livalo |
| Avadel Cns Pharmaceuticals, LLC | $76.98 | 2023-2024 | Lumryz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $76.88 | 2025 | |
| Glaxosmithkline, LLC. | $57.27 | 2025 | Shingrix, Arexvy |
| Zoll Respicardia, INC. | $50.06 | 2024 | Remede System |
| Boston Scientific Corporation | $49.01 | 2022-2025 | Watchman Flx |
| Scpharmaceuticals INC. | $48.18 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $43.67 | 2022-2024 | Eliquis |
| Baxter Healthcare | $42.55 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $42.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $42.01 | 2023 | Quviviq |
| Novo Nordisk INC | $41.76 | 2024 | Ozempic |
| Sanofi-Aventis U.S. LLC | $39.02 | 2022-2023 | |
| Inspire Medical Systems, INC. | $38.20 | 2023 | Inspire |
| Kiniksa Pharmaceuticals, Ltd. | $28.58 | 2022-2023 | Arcalyst |
| 3b Medical, INC. | $24.50 | 2025 | Luna |
| Azurity Pharmaceuticals, INC. | $21.44 | 2023 | Edarbi |
| Arbor Pharmaceuticals, INC. | $19.30 | 2022 | |
| Merck Sharp & Dohme LLC | $12.71 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.